Torrent Pharmaceuticals Limited Stock Price Today (NSE: TORNTPHARM)
Fundamental Score
Torrent Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Torrent Pharmaceuticals Limited share price today is ₹4971.00, up +2.86% on NSE/BSE as of 24 August 2026. Torrent Pharmaceuticals Limited (TORNTPHARM) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.70L (Cr). The 52-week high for TORNTPHARM share price is ₹5250.00 and the 52-week low is ₹3480.60. At a P/E ratio of 77.90x, TORNTPHARM is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 27.07% and a debt-to-equity ratio of 1.76.
Torrent Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Torrent Pharmaceuticals Limited share price chart: 11.53% return over the past month. 52-week high ₹5250.00, 52-week low ₹3480.60.
Torrent Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹4900.00 | ₹5009.00 | ₹4876.00 | ₹4971.00 | 4.27L (Cr) | |
| ₹4888.00 | ₹4915.50 | ₹4833.00 | ₹4833.00 | 1.67L (Cr) | |
| ₹4890.50 | ₹4914.50 | ₹4833.00 | ₹4914.50 | 4.33L (Cr) | |
| ₹4864.00 | ₹4893.50 | ₹4824.50 | ₹4893.00 | 4.01L (Cr) | |
| ₹4942.50 | ₹4942.50 | ₹4831.00 | ₹4886.00 | 3.61L (Cr) | |
| ₹4928.50 | ₹4981.50 | ₹4885.00 | ₹4924.00 | 4.16L (Cr) | |
| ₹4956.00 | ₹4987.50 | ₹4901.00 | ₹4924.00 | 3.94L (Cr) | |
| ₹5020.00 | ₹5030.00 | ₹4937.50 | ₹4956.00 | 7.02L (Cr) | |
| ₹5068.50 | ₹5068.50 | ₹4946.50 | ₹5000.00 | 5.10L (Cr) | |
| ₹5058.00 | ₹5058.50 | ₹4996.00 | ₹5030.00 | 6.58L (Cr) |
Torrent Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹5250.00 | ₹5250.00 | ₹4824.50 | ₹4971.00 | -5.31% | |
| ₹4646.90 | ₹5140.70 | ₹4574.30 | ₹5122.80 | +10.24% | |
| ₹4438.10 | ₹4742.90 | ₹4240.30 | ₹4620.10 | +4.10% | |
| ₹4185.10 | ₹4712.90 | ₹4185.10 | ₹4410.80 | +5.39% | |
| ₹4277.60 | ₹4333.00 | ₹3871.10 | ₹4185.10 | -2.16% | |
| ₹4191.00 | ₹4482.90 | ₹4161.20 | ₹4220.20 | +0.70% | |
| ₹4018.50 | ₹4470.00 | ₹3903.90 | ₹4333.30 | +7.83% | |
| ₹3860.00 | ₹4107.20 | ₹3695.00 | ₹3960.80 | +2.61% | |
| ₹3723.90 | ₹3863.00 | ₹3688.80 | ₹3850.00 | +3.39% | |
| ₹3560.10 | ₹3882.20 | ₹3532.60 | ₹3720.60 | +4.51% | |
| ₹3603.10 | ₹3685.60 | ₹3480.60 | ₹3560.10 | -1.19% | |
| ₹3569.40 | ₹3689.20 | ₹3483.10 | ₹3603.20 | +0.95% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Torrent Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Torrent Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TORNTPHARM across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (27.07%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Strong Operating Margins (30.79%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (54.85%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (8.46x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹10547.15 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (68.31%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 25.14%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 77.90x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (20.25x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-2.88% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Elevated Debt Levels (D/E: 1.76)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Torrent Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Torrent Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Torrent Pharmaceuticals LimitedTorrent Pharmac...Selected✓ TORNTPHARM • 500420 | 51.4/100 | ₹4971.00₹4971 | ₹169902.02₹169902.02 | 77.90Average 77.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹7386.50₹7387 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1415.10₹1415 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Biocon LtdBiocon Ltd... BIOCON • 532523 | 30.2/100 | ₹437.95₹438 | ₹70826.50₹70826.50 | 181.85Average 181.8 Average | 1.40%Poor 1.40% Poor | 3.75%Poor 3.75% Poor | 0.45Excellent 0.5 Excellent | -11.84%Poor -11.84% Poor | 18.83%Excellent 18.83% Excellent | 0.12% |
Abbott India LtdAbbott India Lt... ABBOTINDIA • 500488 | 62.3/100 | ₹28900.00₹28900 | ₹58692.31₹58692.31 | 37.82Average 37.8 Average | 34.46%Excellent 34.46% Excellent | 44.89%Excellent 44.89% Excellent | 0.04Excellent 0.0 Excellent | 17.57%Excellent 17.57% Excellent | 9.96%Good 9.96% Good | 1.90% |
JB Chemicals & Pharmaceuticals LtdJB Chemicals & ... JBCHEPHARM • 506943 | 53.9/100 | ₹2408.90₹2409 | ₹40248.14₹40248.14 | 56.02Average 56.0 Average | 18.93%Good 18.93% Good | 25.45%Excellent 25.45% Excellent | 0.00Excellent 0.0 Excellent | 12.37%Good 12.37% Good | 15.22%Excellent 15.22% Excellent | 0.88% |
Wockhardt LtdWockhardt Ltd... WOCKPHARMA • 532300 | 24.6/100 | ₹1953.40₹1953 | ₹30725.07₹30725.07 | 108.16Average 108.2 Average | 6.11%Poor 6.11% Poor | 7.55%Poor 7.55% Poor | 0.45Excellent 0.5 Excellent | -19.25%Poor -19.25% Poor | 4.49%Average 4.49% Average | 0.00% |
ACUTAAS CHEMICALS LIMITEDACUTAAS CHEMICA... ACUTAAS • 543349 | 62.09999999999999/100 | ₹3659.60₹3660 | ₹29036.77₹29036.77 | 81.50Average 81.5 Average | 24.05%Excellent 24.05% Excellent | 31.56%Excellent 31.56% Excellent | 0.02Excellent 0.0 Excellent | 45.77%Excellent 45.77% Excellent | 31.50%Excellent 31.50% Excellent | 0.04% |
Sequent Scientific LtdSequent Scienti... SEQUENT • 512529 | 63.9/100 | ₹188.78₹189 | ₹12241.20₹12241.20 | 61.29Average 61.3 Average | 11.05%Average 11.05% Average | 19.05%Good 19.05% Good | 0.17Excellent 0.2 Excellent | 15.00%Excellent 15.00% Excellent | 20.23%Excellent 20.23% Excellent | 0.00% |
Aarti Pharmalabs LtdAarti Pharmalab... AARTIPHARM • 543748 | 9.1/100 | ₹672.70₹673 | ₹6511.24₹6511.24 | 36.83Average 36.8 Average | 8.59%Poor 8.59% Poor | 10.70%Average 10.70% Average | 0.36Excellent 0.4 Excellent | — — | — — | 0.70% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Divis Laboratories Ltd share price193163.97 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
- Biocon Ltd share price70826.50 Cr
- Abbott India Ltd share price58692.31 Cr
Torrent Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for TORNTPHARM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹56.47 | ₹3850.00 | 68.2x |
| FY 2024 | ₹48.94 | ₹3360.05 | 68.7x |
| FY 2023 | ₹36.79 | ₹2305.55 | 62.7x |
| FY 2022 | ₹22.96 | ₹1550.60 | 67.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Torrent Pharmaceuticals Limited Dividend History
Annual cash dividends paid by TORNTPHARM — dividend yield 0.76%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1083.03 Cr |
| FY 2024 | ₹1015.34 Cr |
| FY 2023 | ₹863.04 Cr |
| FY 2022 | ₹676.89 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Torrent Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for TORNTPHARM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
54.85%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
3.28%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.80%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
11.56%
Compounded annual net profit growth over 5 years
Torrent Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for TORNTPHARM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Torrent Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Torrent Pharmaceuticals Limited (TORNTPHARM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Torrent Pharmaceuticals Limited
About TORNTPHARM (Torrent Pharmaceuticals Limited)
Torrent Pharmaceuticals Ltd is a global pharmaceutical powerhouse driven by a relentless pursuit of innovation and a deep commitment to improving patient lives. They operate on a f...oundation of robust research and development, crafting both branded and generic formulations that address a spectrum of medical needs. From the bustling laboratories where new treatments are conceived to the advanced manufacturing facilities where they are brought to life, Torrent Pharmaceutical's commitment to quality and efficacy is evident. Their dedication extends beyond simply creating medicine; it encompasses a global network of distribution channels, ensuring their products reach those who need them most across diverse international markets. The company's therapeutic scope is broad, covering areas crucial to modern healthcare. They are key players in developing treatments for chronic conditions like diabetes and cardiovascular diseases, as well as tackling infectious diseases and managing pain. Their product portfolio extends to specialized fields such as oncology, neurology, and nephrology, showcasing their versatility and dedication to addressing complex medical challenges. Beyond their core therapeutic areas, Torrent Pharmaceuticals also recognizes the importance of overall well-being, offering solutions in areas like gynecology, dermatology, and gastrointestinal health. This multifaceted approach reflects a comprehensive understanding of the diverse needs of patients across the globe. Torrent Pharmaceuticals' global reach extends far beyond their Indian roots, with a significant presence in key markets like the United States, Brazil, and Germany. This international expansion is a testament to their ability to adapt to diverse regulatory landscapes and meet the unique demands of various healthcare systems. By forging strategic partnerships and investing in local infrastructure, Torrent Pharmaceuticals ensures its products are accessible and affordable to patients worldwide. Their commitment to global health is further underscored by their dedication to ethical practices and sustainable operations, positioning them as a responsible and trusted leader in the pharmaceutical industry.
Company Details
Key Leadership
Corporate Events
TORNTPHARM Share Price: Frequently Asked Questions
What is the current share price of Torrent Pharmaceuticals Limited?
Torrent Pharmaceuticals Limited (TORNTPHARM) trades at ₹4971.00 on NSE and BSE. Market cap ₹1.70L (Cr). Educational data only.
What is the P/E ratio of Torrent Pharmaceuticals Limited?
Torrent Pharmaceuticals Limited has a P/E of 77.90x vs industry average 34.89x.
What is the Bull Run score for Torrent Pharmaceuticals Limited?
Torrent Pharmaceuticals Limited has a Bull Run score of 51.4/100 based on 25+ financial parameters.
Does Torrent Pharmaceuticals Limited pay dividends?
Torrent Pharmaceuticals Limited has a dividend yield of 0.76%. Past dividends don't guarantee future payments.
What is the ROE of Torrent Pharmaceuticals Limited?
Torrent Pharmaceuticals Limited has ROE of 27.07%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Torrent Pharmaceuticals Limited?
Torrent Pharmaceuticals Limited has debt-to-equity of 1.76.
Is Torrent Pharmaceuticals Limited a good investment?
Bull Run gives Torrent Pharmaceuticals Limited a score of 51.4/100. This is not investment advice — consult a SEBI-registered advisor.